Cancer Letters
Volume 225, Issue 1 , Pages 105-110 , 8 July 2005

Survivin expression in chronic myeloid leukemia

  • Enrico Conte

      Affiliations

    • Department of Biomedical Sciences, Pathology Section, University of Catania, via Androne 83, Catania I-95124, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39 095313429; fax: +39 095320267.
    • The first two authors contributed equally.
    • ,
  • Fabio Stagno

      Affiliations

    • Department of Biomedical Sciences, Hematology Sections, University of Catania, via Androne 83, Catania I-95124, Italy
    • The first two authors contributed equally.
    • ,
  • Patrizia Guglielmo

      Affiliations

    • Department of Biomedical Sciences, Hematology Sections, University of Catania, via Androne 83, Catania I-95124, Italy
    • ,
  • Anna Scuto

      Affiliations

    • Department of Biomedical Sciences, Pathology Section, University of Catania, via Androne 83, Catania I-95124, Italy
    • ,
  • Carla Consoli

      Affiliations

    • Department of Biomedical Sciences, Hematology Sections, University of Catania, via Androne 83, Catania I-95124, Italy
    • ,
  • Angelo Messina

      Affiliations

    • Department of Biomedical Sciences, Pathology Section, University of Catania, via Androne 83, Catania I-95124, Italy

Received 20 September 2004 ,Revised 20 October 2004 ,Accepted 22 October 2004.

References 

  1. Verfaille CM. Biology of chronic myelogenous leukemia. Hematol. Oncol. Clin. North Am. 1998;12:1–29
  2. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Joness RJ. Inhibition of apoptosis in chronic myeloid leukemia. Blood. 1994;83:2038–2044
  3. Jaattela M. Escaping cell death: survival proteins in cancer. Exp. Cell Res. 1999;248:30–43
  4. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456–1462
  5. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family. Blood. 1996;88:386–401
  6. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature. 2000;407:810–816
  7. Salvesen GS, Duckett CS, proteins: IAP. blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 2002;3:401–410
  8. Ambrosini G, Adida C, Altieri D. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997;3:917–921
  9. Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 1999;17:2100–2104
  10. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071–5074
  11. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of anti-apoptosis molecule survivin and recurrence of bladder cancer. New Engl. J. Med. 1999;341:452–453
  12. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer. 2001;95:92–95
  13. Altieri DC. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer. 2003;3:46–54
  14. Fukuda S, Foster RG, Porter SB, Pelus LM. The antiapoptosis protein survivin is associated with cell cycle entry of normal cord blood CD34+ cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood. 2002;100:2463–2471
  15. Fukuda S, Pelus ML. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34+ cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood. 2001;98:2091–2100
  16. Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukemia. Br. J. Haematol. 2000;111:96–203
  17. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–1925
  18. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann. Int. Med. 1999;131:207–219
  19. Ginzinger DG. Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp. Hematol. 2002;30:503–512
  20. Van Dongen JJM, Macintyre EA, Gabert GA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13:1901–1928
  21. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 2001;7:542–547
  22. Carter BZ, Milella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood. 2001;97:2784–2790
  23. Badran A, Yoshida A, Wano Y, Imamura S, Kawai Y, Tsutani H, et al. Expression of the antiapoptotic gene survivin in chronic myeloid leukaemia. Anticancer Res. 2003;23(1B):589–592
  24. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351:882–883

PII: S0304-3835(04)00842-0

doi: 10.1016/j.canlet.2004.10.034

Cancer Letters
Volume 225, Issue 1 , Pages 105-110 , 8 July 2005

Article Tools

* Image Usage & Resolution